Theralase Technologies Inc. | Income Statement
Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,203.60
1,380.60
1,945.20
1,918.90
2,342.50
1,734.10
Cost of Goods Sold (COGS) incl. D&A
480.70
542.20
764.60
945.90
1,198.90
1,009.40
Gross Income
722.90
838.40
1,180.60
973.00
1,143.60
724.70
SG&A Expense
1,900.20
3,592.40
6,733.10
6,079.70
7,410.80
4,231.90
EBIT
1,177.30
2,754.00
5,552.40
5,106.70
6,267.20
3,507.20
Non Operating Income/Expense
14.10
4.60
7.90
30.00
15.50
8.30
Interest Expense
42.80
19.50
0.80
-
-
-
Pretax Income
1,225.60
2,760.60
5,508.10
5,121.20
6,276.00
3,496.90
Income Tax
73.40
173.00
300.00
200.00
182.50
140
Consolidated Net Income
1,152.20
2,587.50
5,208.10
4,921.20
6,093.60
3,356.90
Net Income
1,152.20
2,587.50
5,208.10
4,921.20
6,093.60
3,356.90
Net Income After Extraordinaries
1,152.20
2,587.50
5,208.10
4,921.20
6,093.60
3,356.90
Net Income Available to Common
1,152.20
2,587.50
5,208.10
4,921.20
6,093.60
3,356.90
EPS (Basic)
0.02
0.03
0.05
0.04
0.05
0.03
Basic Shares Outstanding
47,853.90
74,979.50
101,382.80
109,035.60
124,094.10
130,488.20
EPS (Diluted)
0.02
0.03
0.05
0.05
0.05
0.03
Diluted Shares Outstanding
47,853.90
74,979.50
101,382.80
109,035.60
124,094.10
130,488.20
EBITDA
1,099.80
2,670.20
5,417.40
4,957.40
6,013.30
3,284.30
Non-Operating Interest Income
8.50
8.40
37.20
15.40
6.60
18.60
About Theralase Technologies
View Profile
